The FDA warned health-care providers to stick to dosing recommendations for Intercept Pharma’s liver disease medicine Ocaliva after 19 patient deaths were reported.
Roche received European approval for its Actemra medication in giant cell arteritis (GCA) and Gazyvaro for people with previously untreated advanced follicular lymphoma.
People who exercise five days a week for 30 minutes significantly reduce their risk of dying early and of developing heart disease, even if a sports club or gym is not an option, according to a new international study.
In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market.
U.S. Vice President Mike Pence urged fellow Republicans to get behind the party’s “last best chance” to repeal and replace Obamacare as congressional leaders scrambled to secure enough support ahead of a planned vote.
Precision Medicine Group Announces Formation of Comprehensive Service Offering–Precision Value & Health
Precision Medicine Group, a specialized services company supporting next generation approaches to drug development and commercialization, today announced the formation of Precision Value & Health—a focused set of complementary services working in concert to help pharmaceutical and life sciences clients establish the clinical, economic, and humanistic value of innovative therapies to payers, healthcare professionals, and patients.
Noted biotech investor G. Steven Burrill faces up to 30 years in prison for his alleged involvement in wire fraud and tax evasion.
Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.
Makers of generic AIDS drugs will start churning out millions of pills for Africa containing a state-of-the-art medicine widely used in rich countries, after securing a multi-million dollar guarantee that caps prices at just $75 per patient a year.
Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said.